TAK-195
/ Takeda
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 22, 2020
Safety and immunogenicity of experimental stand-alone trivalent, inactivated Sabin-strain polio vaccine formulations in healthy infants: A randomized, observer-blind, controlled phase 1/2 trial.
(PubMed, Vaccine)
- "A novel stand-alone Sabin-based IPV vaccine was well tolerated with an acceptable safety profile, but less immunogenic than reference Salk IPV at 6, 10 and 14 weeks of age for Salk serotypes 1 and 2, with apparent interference by maternal antibodies. Additional preclinical assessments will be made before any further clinical development."
Clinical • Journal • P1/2 data
1 to 1
Of
1
Go to page
1